KES-0001 is under clinical development by Kesios Therapeutics and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase II drugs for Refractory Multiple Myeloma have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how KES-0001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DTP-3 (KES-0001) was under development for the treatment of relapsed or refractory multiple myeloma, diffuse large b-cell lymphoma, primary mediastinal b-cell lymphoma, high-grade b-cell lymphoma. DTP-3 is a tripeptide administered intravenously. The therapeutic candidate disrupts GADD45beta (growth arrest and DNA damage-inducible protein) and MKK7 (mitogen-activated protein kinase kinase 7) complex.
Kesios Therapeutics overview
Kesios Therapeutics Limited, an oncology drug discovery company that develops small molecule drugs for haematological malignancies. The company is headquartered in United Kingdom.
For a complete picture of KES-0001’s drug-specific PTSR and LoA scores, buy the report here.